» Articles » PMID: 15489957

Epithelial Hypoxia-inducible Factor-1 is Protective in Murine Experimental Colitis

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2004 Oct 19
PMID 15489957
Citations 342
Authors
Affiliations
Soon will be listed here.
Abstract

Mucosal epithelial cells are uniquely equipped to maintain barrier function even under adverse conditions. Previous studies have implicated hypoxia in mucosal tissue damage resulting from both acute and chronic inflammation. Given the importance of the transcriptional regulator hypoxia-inducible factor-1 (HIF-1) for adaptive hypoxia responses, we hypothesized that HIF-1 may serve as a barrier-protective element during mucosal inflammation. Initial studies of hapten-based murine colitis revealed extensive mucosal hypoxia and concomitant HIF-1 activation during colitis. To study this in more detail, we generated 2 mouse lines with intestinal epithelium-targeted expression of either mutant Hif1a (inability to form HIF-1) or mutant von Hippel-Lindau gene (Vhlh; constitutively active HIF-1). Studies of colitis in these mice revealed that decreased HIF-1 expression correlated with more severe clinical symptoms (mortality, weight loss, colon length), while increased HIF levels were protective in these parameters. Furthermore, colons with constitutive activation of HIF displayed increased expression levels of HIF-1-regulated barrier-protective genes (multidrug resistance gene-1, intestinal trefoil factor, CD73), resulting in attenuated loss of barrier during colitis in vivo. Taken together, these studies provide insight into tissue microenvironmental changes during model inflammatory bowel disease and identify HIF-1 as a critical factor for barrier protection during mucosal insult.

Citing Articles

Modulation of β-Catenin promotes WNT expression in macrophages and mitigates intestinal injury.

Chugh R, Bhanja P, Zitter R, Gunewardena S, Badkul R, Saha S Cell Commun Signal. 2025; 23(1):78.

PMID: 39934819 PMC: 11818365. DOI: 10.1186/s12964-025-02065-7.


Real-world of Limosilactobacillus reuteri in mitigation of acute experimental colitis.

Yue N, Zhao H, Hu P, Zhang Y, Tian C, Kong C J Nanobiotechnology. 2025; 23(1):65.

PMID: 39891249 PMC: 11783912. DOI: 10.1186/s12951-025-03158-8.


Intestinal oxygen utilisation and cellular adaptation during intestinal ischaemia-reperfusion injury.

Archontakis-Barakakis P, Mavridis T, Chlorogiannis D, Barakakis G, Laou E, Sessler D Clin Transl Med. 2024; 15(1):e70136.

PMID: 39724463 PMC: 11670310. DOI: 10.1002/ctm2.70136.


The impact of aerobic and anaerobic exercise interventions on the management and outcomes of non-alcoholic fatty liver disease.

Qi F, Li T, Deng Q, Fan A Physiol Res. 2024; 73(5):671-686.

PMID: 39530904 PMC: 11629946. DOI: 10.33549/physiolres.935244.


HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.

Shen H, Ojo O, Ding H, Mullen L, Xing C, Hossain M Nat Commun. 2024; 15(1):9394.

PMID: 39477954 PMC: 11526104. DOI: 10.1038/s41467-024-53593-8.


References
1.
Tacchini L, Bianchi L, Bernelli-Zazzera A, Cairo G . Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem. 1999; 274(34):24142-6. DOI: 10.1074/jbc.274.34.24142. View

2.
Hermiston M, Gordon J . Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 1995; 270(5239):1203-7. DOI: 10.1126/science.270.5239.1203. View

3.
Furuta G, Turner J, Taylor C, Hershberg R, Comerford K, Narravula S . Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001; 193(9):1027-34. PMC: 2193432. DOI: 10.1084/jem.193.9.1027. View

4.
Iyer N, Kotch L, Agani F, Leung S, Laughner E, Wenger R . Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998; 12(2):149-62. PMC: 316445. DOI: 10.1101/gad.12.2.149. View

5.
Laughlin K, Evans S, JENKINS W, Tracy M, Chan C, Lord E . Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 1996; 277(2):1049-57. View